Mark Schoenberg - 09 Jul 2026 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Reporting relationship: Chief Medical Officer
Issuer ticker: URGN
Reported as of: 09 Jul 2026
Net transaction value: -$400,000
SEC form: 4
Accepted by SEC: 10 Jul 2026, 14:17:40 UTC
Prior SEC filing: 24 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Jason D. Smith, Attorney-in-Fact

Key filing fact

Mark Schoenberg filed Form 4 for UroGen Pharma Ltd. (URGN) on 10 Jul 2026.

Key facts

This page summarizes Mark Schoenberg's Form 4 filing for UroGen Pharma Ltd. (URGN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 10 Jul 2026, 14:17.

Change

Previous filing in this sequence was filed on 24 Jun 2026.
Current net transaction value: -$400,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001763581 Primary reporting owner

Schoenberg Mark

Relationship: Chief Medical Officer
Address: 400 ALEXANDER PARK DRIVE, PRINCETON
Signature: /s/ Jason D. Smith, Attorney-in-Fact
Signature date: 10 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

URGN transaction

Ordinary Shares

Sale

Transaction value: $400,000
Shares: -10,000
Change %: -7.7%
Price: $40.00
Shares after: 119,763
Date: 09 Jul 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Transaction made pursuant to a duly adopted trading plan under Rule 10b5-1(c). The adoption date of the referenced Rule 10b5-1(c) plan is August 15, 2025. This transaction represents the final sale under such trading plan.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 and $40.02. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.